US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Hemab Therapeutics (COAG): Blood Coagulation Disorder Biotech Sets Terms for IPO

Hemab Therapeutics (COAG): Peeking at the IPO Prospectus of a Blood Coagulation Disorder Biotech

Hemab Therapeutics (COAG): RA Capital-Backed Bio Sees Robust IPO Interest

IPOs and Secondary Offerings

Equity Capital Markets

Hemab Therapeutics / Equity Capital Markets

<ul>
<li>Priced at $18.00 and opened at $27.00, closing at $34.00 (+88.9%) after trading as high as $36.61.</li>
<li>Heavily oversubscribed deal with concentrated allocations; top 10 investors received ~75% of shares, driving scarcity and momentum.</li>
<li>Second-Best IPO of 2026 behind Veradermics; strong RA Capital backing and tight float supported powerful aftermarket performance.</li>
</ul>


Priced at $18.00 and opened at $27.00, closing at $34.00 (+88.9%) after trading as high as $36.61.
Heavily oversubscribed deal with concentrated allocations; top 10 investors received ~75% of shares, driving scarcity and momentum.
Second-Best IPO of 2026 behind Veradermics; strong RA Capital backing and tight float supported powerful aftermarket performance.


Hemab Therapeutics (COAG)：RA Capitalが再び好調、Hemab株は初日に急騰